Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825019 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
A Phase 3 study of Major Depressive Disorders, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 306
- Enrollment target
- 1
- Study location
NCT00825019 is a Phase 3 study of Major Depressive Disorders that has completed, run by Sanofi. The registered enrollment target is 306 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00825019, a Phase 3 study of Major Depressive Disorders, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 306 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive episode (MDD). Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.
Conditions Studied
Interventions
- DRUG placebo
- DRUG paroxetine
- DRUG amibegron (SR58611A)
Study Locations (1)
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00825019
The ClinicalTrials.gov registry entry for NCT00825019 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorders appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00825019 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00825019 about?
NCT00825019 is a clinical study titled "Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine". Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive episode (MDD). Secondary objective is to assess the safety profile of ...
What is the current status of trial NCT00825019?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 306 participants. The study started on 2003-09. Estimated completion is 2004-12.
What conditions does trial NCT00825019 study?
This clinical trial studies the following conditions: Major Depressive Disorders.
What interventions are being tested in trial NCT00825019?
The interventions under investigation include: placebo (DRUG), paroxetine (DRUG), amibegron (SR58611A) (DRUG).
Who is sponsoring clinical trial NCT00825019?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00825019 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.